Delivery Order SPE2DB22D3016-SPE2DB24FAZR6
- Not listed
- This federal contract award, valued at $42,155.20, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TAGRISSO 80 MG TABLET 30S, a medication, and has a completion date of November 21, 2024. The contract was awarded on October 30, 2024 and is structured as a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen holds a $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,662.57 firm-fixed-price delivery order is for the supply of TAGRISSO 80 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of March 26, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award, valued at $10,662.57, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for TAGRISSO 80 MG TABLET 30S, with an ultimate completion date of April 16, 2025. The contract is a Firm Fixed Price arrangement, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,508.31, is a delivery order for the supply of TAGRISSO 40 MG TABLET 30S, a medical product. The contract has a completion date of January 29, 2024 and is a firm fixed-price arrangement. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award, valued at $10,662.57, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of March 6, 2025. The contract covers the procurement of pharmaceutical products, including the drug TAGRISSO 80 MG TABLET 30S, to support military healthcare programs. AmerisourceBergen holds a...
- This federal contract award, valued at $10,662.57, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TAGRISSO 80 MG TABLET 30S, a pharmaceutical product, with a period of performance through April 1, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,538.79 firm fixed-price delivery order is for the medication TAGRISSO 80 MG TABLET 30S, with a completion date of March 15, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $105,387.90 Firm Fixed Price Delivery Order contract is for the supply of TAGRISSO 80 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of July 5, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,662.57 firm fixed price delivery order is for TAGRISSO 80 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of April 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,538.79 firm fixed-price delivery order is for TAGRISSO 80 MG TABLET 30S, a specialty medication. The contract has an ultimate completion date of February 7, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB24FAZR6Delivery Order
This federal contract award, valued at $56,140.37, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the drug TAGRISSO 80 MG TABLET 30S, a medical product used for various healthcare applications. The contract has an ultimate completion date of July 22, 2024 and is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award is part of the company's broader federal contract portfolio, which also includes a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $56.1k | 6/28/24 |